ET
RARE icon

Entropy Technologies’s Ultragenyx Pharmaceutical RARE Stock Holding History

Entropy Technologies’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.3M Buy
109,727
+49,086
+81% +$1.11M 0.11% 255
2025
Q4 		$1.39M Buy
60,641
+40,577
+202% +$1.33M 0.08% 315
2025
Q3 		$604K Buy
20,064
+8,728
+77% +$262K 0.05% 469
2025
Q2 		$412K Buy
11,336
+3,787
+50% +$137K 0.03% 535
2025
Q1 		$273K Buy
+7,549
New +$314K 0.03% 559

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Entropy Technologies's RARE Position: Q1 2026 in Review

Entropy Technologies increased its Ultragenyx Pharmaceutical (RARE) stake by 81% in Q1 2026, buying an estimated $1.11M and bringing the position to 109,727 shares worth $2.3M. The position accounts for 0.11% of the portfolio, ranked #255.

Entropy Technologies first reported a position in RARE in Q1 2025 and has held it in 5 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Entropy Technologies held 109,727 shares of Ultragenyx Pharmaceutical worth $2.3M as of Q1 2026.
  • Entropy Technologies bought 49,086 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.11M.
  • Ultragenyx Pharmaceutical made up 0.11% of Entropy Technologies's portfolio in Q1 2026, its #255 holding.
  • Entropy Technologies first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.